Helicobacter pylori[ edit ] Helicobacter pylori colonizes the stomachs of more than half of the world's population, and the infection continues to play a key role in the pathogenesis of a number of gastroduodenal diseases. Colonization of the gastric mucosa with Helicobacter pylori results in the development of chronic gastritis in infected individuals, and in a subset of patients chronic gastritis progresses to complications e. Gastritis may also occur in those who have had weight loss surgery resulting in the banding or reconstruction of the digestive tract. Diet[ edit ] Evidence does not support a role for specific foods including spicy foods and coffee in the development of peptic ulcers.
April 1, Content info: Proton pump inhibitors PPIs are a group of drugs whose main action is the long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. Increasing Prevalence of Gastroesophageal Reflux Disease GERD Gastroesophageal reflux disease is a chronic condition, where stomach contents come back up into the esophagus resulting in either symptoms or complications.
In a research study, it was estimated that GERD prevalence was estimated at In addition to the increase in prevalence, people with risk factors, such as obesity, tobacco use and others, are also increasing in almost every part of the world. Obesity, which is the major risk factor of GERD is increasing rapidly in developed countries, such as the United States, the United Kingdom, and others.
Increasing prevalence of GERD, along with growing risk factor population will lead to growth in demand for proton pump inhibitors, which in turn, will drive the market.
Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market. Increasing Generic Products Over the next decade, the proton pump inhibitors market is expected to be constrained by generic competition to key therapies. Many Innovator drugs have already lost their patents.
Generic alternatives for these drugs have already been approved, which will result in future generic competition over the forecast period.
However, due to the time delay in drug submission in Canada and Japan, the impact of patent expirations will not be as immediate. In addition, the impact of the patent expiration of Nexium in will continue to have an affect on the market growth during the forecast period due to the availability of its generic competitors.
Even the entry of new drugs is not expected to be significant enough to diminish the impact of generic competition.
As new entrants will be competing against cheaper generic products, they are not expected to demand a premium price.
This generic competition to new entrants is expected to restrain the market during the forecast period. United States Leads the Market in North America The United States proton pump inhibitors market held the largest market share in in North America due to the growing prevalence of gastrointestinal disorders, and is likely to contribute towards the growth of the proton pump inhibitors market.
Key Developments in the Market March Reasons to Purchase the Report Follow the current and future proton pump inhibitors market in the developed and emerging markets. Identify the segment that is expected to dominate the market. Identify the regions that are expected to witness the fastest growth during the forecast period.
Identify the latest developments, market shares, and strategies employed by the major market players. Customization of the Report This report can be customized to meet your requirements.
Please connect with our representative, who will ensure you to get a report that suits your needs.This report studies Proton Pump Inhibitor Drug in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from to , and forecast to Notes: Production, means the output of Proton Pump Inhibitors Revenue, means the sales value of Proton Pump Inhibitors This report studies Proton Pump Inhibitors in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering.
This report studies the global Proton Pump Inhibitors (PPIs) market status and forecast, categorizes the global Proton Pump Inhibitors (PPIs) market size (value & volume) by manufacturers, type, application, and region.
In this report, the global Proton Pump Inhibitors (PPIs) market is valued at USD XX million in and is expected to reach USD XX million by the end of , growing at a CAGR of XX% between and Geographically, this report is segmented into several key Regions, with production, consu.
Open Access Initiative is committed to make genuine and reliable contributions to the scientific community without restricting the access of published content.
Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a long duration. There may be no symptoms but, when symptoms are present, the most common is upper abdominal pain.
Other possible symptoms include nausea and vomiting, bloating, loss of appetite and heartburn. Complications may include bleeding, stomach ulcers, and stomach tumors.